La cadena de opciones muestra datos clave de las opciones de acciones de Wizz Air Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Wizz Air Holdings..

Wizz Air Holdings (OTC:WZZZY) Bolsa, Cadena de Opciones

Wizz Air is a prominent ultralow-cost airline group operating primarily across Europe, the Middle East, North Africa, and Northwest Asia. Founded in 2003, the company offers scheduled short-haul and medium-haul point-to-point flights under the Wizz Air brand. As of March 2024, Wizz Air operated a fleet of 208 aircraft, connecting approximately 200 destinations across 50 countries.

WIZZ AIR HOLDINGS UNS/ADR by Wizz Air Holdings PLC

Wizz Air Holdings PLC

JMP Securities analyst Steven DeLaney reiterates Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) with a Market Outperform and maintains $15 price target.

News

Price Target

Reiteration

Analyst Ratings

FBRT

JMP Securities Reiterates Market Outperform on Franklin BSP Realty Trust, Maintains $15 Price Target

Truist Securities analyst Michael Ciarmoli maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $205 to $209.

Truist Securities Maintains Buy on Woodward, Raises Price Target to $209

Truist Securities analyst Gregory Miller maintains OneSpaWorld Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) with a Buy and lowers the price target from $22 to $19.

Truist Securities Maintains Buy on OneSpaWorld Hldgs, Lowers Price Target to $19

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $210 to $199.

BIIB

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $199

Zebra Technologies Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) stock gained on Tuesday after it reported financial results for&nbsp;<a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">the </a>first <a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">quarter</a>. Here's what you need to know.
The mobile computing company reported quarterly sales of $1.31 billion, up by 11.3%, beating analyst estimates of $1.29 billion.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" target="_blank" rel="noreferrer noopener">Zebra Tech Q4 Earnings: Revenue Surges 32%, CEO Cites Strong Retail Demand</a>
Zebra reported adjusted earnings of $4.02 per share, exceeding&nbsp;analyst estimates of $3.62.
Zebra's two main business segments also saw substantial growth during the period. The Enterprise Visibility &amp; Mobility segment recorded net sales of $846 million, up 8% from the previous year. The Asset Intelligence &amp; Tracking segment recorded net sales of $462 million, up 17.9% from the previous year.
The consolidated adjusted gross margin increased 150 bps to 49.6%, primarily due to volume leverage and business mix. Adjusted EBITDA margin expanded by 240 bps to 22.3%.
The company said it had $879 million in cash and cash equivalents as of March 29.
CEO Bill Burns said demand trends continued to be positive into the second quarter, and the company left its full-year outlook unchanged, except for the direct cost of tariffs.&nbsp;
Outlook:&nbsp;For the second quarter, Zebra expects sales growth of 4%-7% or $1.25 billion-$1.30 billion versus the&nbsp;$1.28 billion estimate. The company expects adjusted earnings of $3-$3.50 per share <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">versus estimates of</a> $3.52.
The company reiterated fiscal 2025 net sales growth of 3%-7% or $5.13 billion-$5.33 billion versus the $5.37 billion estimate. It expects adjusted earnings of $13.75-$14.75 (<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" rel="noreferrer noopener">prior $14.75-$15.25</a>) per share versus the $15.89 per share estimate.
ZBRA Price Action:&nbsp;Zebra stock is up 6.57% at 259.49 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback" target="_blank" rel="noreferrer noopener">Alibaba Bets Big On AI With New Cloud Tools As Jack Ma Reemerges In Company Comeback</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock

Earnings

Guidance

Movers

ZBRA

Zebra Stock Rises As Strong Retail Demand, Sales Beat Drive Big Quarter, But Tariffs Cloud Full-Year Outlook

JMP Securities analyst Silvan Tuerkcan reiterates enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform and maintains $18 price target.

ENGN

JMP Securities Reiterates Market Outperform on enGene Holdings, Maintains $18 Price Target

B of A Securities analyst Allen Lutz maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Underperform and raises the price target from $22 to $26.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $26

B of A Securities analyst Jean Ann maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underperform and raises the price target from $49 to $50.

B of A Securities Maintains Underperform on Cheniere Energy Partners, Raises Price Target to $50

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $46 price target.

CDTX

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $46 Price Target

JMP Securities analyst Mitch Germain reiterates Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Market Outperform and maintains $21 price target.

JMP Securities Reiterates Market Outperform on Broadstone Net Lease, Maintains $21 Price Target

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.58% on an annualized basis producing an average annual return of 11.78%. Currently, AbbVie has a market capitalization of $344.00 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $300.66 today based on a price of $194.46 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745943312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ABBV

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

Citigroup analyst Paul Diamond initiates coverage on Diversified Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) with a Buy rating and announces Price Target of $16.

Initiation

Citigroup Initiates Coverage On Diversified Energy with Buy Rating, Announces Price Target of $16

B of A Securities analyst Jean Ann Salisbury maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Buy and raises the price target from $254 to $258.

B of A Securities Maintains Buy on Cheniere Energy, Raises Price Target to $258

B of A Securities analyst Jean Ann Salisbury maintains Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy and lowers the price target from $14 to $12.

B of A Securities Maintains Buy on Venture Global, Lowers Price Target to $12

Citigroup analyst Patrick Cunningham maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Neutral and lowers the price target from $66 to $58.

Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $58

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) announced a <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-term collaboration</a> on Tuesday.
In March, Novo Nordisk introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
Americans can now access NovoCare Pharmacy directly through the Hims &amp; Hers platform. A bundled offering of all dose strengths of Wegovy and a Hims &amp; Hers membership, which includes access to 24/7 care, ongoing clinical support, and <a href="https://www.benzinga.com/pressreleases/25/04/b45063485/hims-hers-and-novo-nordisk-team-up-to-expand-affordable-access-to-care" target="_blank" rel="noreferrer noopener">nutrition guidance</a>.
In March, Novo Nordisk announced updates to the Wegovy&nbsp;savings program, allowing all eligible cash-paying patients to access Wegovy&nbsp;(semaglutide) injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44455562/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wego" rel="noreferrer noopener">cost of&nbsp;$499&nbsp;per month</a>.
Previously, the&nbsp;$499-per-month offer for Wegovy&nbsp;was only available via the recently launched NovoCare&nbsp;Pharmacy.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45019869/novo-nordisk-wins-legal-battle-to-curb-unsafe-knockoff-versions-of-ozempic-wegovy" rel="noreferrer noopener">Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy</a>
On Tuesday, the company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims &amp; Hers platform.
The companies are also developing a roadmap that combines Novo Nordisk&#8217;s treatments with Hims &amp; Hers&#8217; ability to scale access to quality care, aiming to improve long-term outcomes for more people.
This new offering builds on Hims &amp; Hers&#8217; existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
The platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans.
Earlier in April, Hims &amp; Hers Health said it would offer Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound <a href="https://www.benzinga.com/25/04/44593851/hims-hers-health-stock-jumped-tuesday-afternoon-what-happened" target="_blank" rel="noreferrer noopener">through its Telehealth platform</a>.
In a blog post, Hims &amp; Hers announced that it's expanding access to personalized weight loss care.
Hims &amp; Hers said its GLP-1 offering generated over $225 million in <a href="https://www.benzinga.com/general/health-care/25/03/44144092/why-is-hims-hers-health-stock-trading-lower-on-wednesday" target="_blank" rel="noreferrer noopener">revenue in 2024</a>.
Price Action: HIMS stock is up 35.5% at $38.60 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45065830/ups-delivers-mixed-bag-q1-supply-chain-weakness-offset-by-strong-domestic-and-international-growth" target="_blank" rel="noreferrer noopener">UPS Delivers Mixed Bag: Q1 Supply Chain Weakness Offset By Strong Domestic And International Growth</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

Contracts

General

Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform

B of A Securities analyst Vivek Arya maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Buy and raises the price target from $320 to $350.

CDNS

B of A Securities Maintains Buy on Cadence Design Systems, Raises Price Target to $350

American consumers are growing sharply more pessimistic, with expectations about their financial future plunging to the lowest levels since October 2011. 
Inflation expectations spike as job prospects darken, underscoring the economic challenges surfacing as President Donald Trump <a href="https://apnews.com/article/trump-100-days-michigan-whitmer-2e30695aa185a785cc1037ab74c19a55">celebrates</a> his first 100 days in office with a rally in Michigan.
In a report shared Tuesday by The Conference Board, the Consumer Confidence Index dropped 7.9 points in April to 86, the lowest reading since March 2023 and part of a five-month losing streak. 
The Expectations Index, which reflects consumers' outlook on income, business and labor conditions for the next six months, collapsed to 54.4, a 13-year low not seen since October 2011. Historically, values below 80 have preceded recessions in the U.S.
<h3 class="wp-block-heading">Pervasive Pessimism Grips US Consumers</h3>
The April drop "was largely driven by consumers' expectations," said Stephanie Guichard, senior economist at The Conference Board. All three subcomponents—future business conditions, employment, and income—showed a sharp deterioration, she added.
"Notably, the share of consumers expecting fewer jobs in the next six months was 32.1%, which is nearly as high as in April 2009, in the middle of the Great Recession," Guichard said.
The proportion of consumers anticipating an income decline also rose, hitting 18.2% in April from 14.9% in March. 
Meanwhile, only 15% expect their income to rise—down from 17.1%—marking the first time in five years that income expectations turned clearly negative, a sign that Americans are not just anxious about the economy at large but also increasingly doubtful about their personal financial situations.
Consumer spending intentions—a key indicator of future demand—are also faltering. The six-month moving average shows declining plans to purchase homes, cars and vacations. 
April saw a pullback in intentions to buy major appliances and electronics, although those figures remain higher compared to earlier months.
Even spending on services, which had been resilient, showed weakness. While dining out remains the top spending priority among services, the share of consumers planning to spend more in this category posted one of the steepest monthly declines on record.
<h3 class="wp-block-heading">Inflation Expectations Soar Amid Tariff Concerns</h3>
Average inflation expectations for the next 12 months jumped to 7%, the highest level since November 2022. 
In an environment where the Federal Reserve has yet to resume interest rate cuts, persistently high inflation expectations could be a red flag for policymakers hoping to avoid stalling economic growth.
At the same time, equity market turbulence appears to be adding to consumer anxiety. According to the Conference Board, 48.5% of respondents expect stock prices to decline over the next year—the highest proportion since 2011.
"High financial market volatility in April pushed consumers' views about the stock market deeper into negative territory," Guichard said.
One of the most unexpected findings from April's survey was a surge in concern over tariffs. 
Consumer write-ins revealed that worries about rising tariffs and their impact on prices are at an all-time high. 
While inflation and cost-of-living pressures remain dominant themes, new mentions of tariffs suggest that geopolitical and trade-related risks are starting to affect household sentiment.
<h3 class="wp-block-heading">Recession Fears Take Hold</h3>
Beyond the headline figures, one of the clearest warning signals is the rise in the share of consumers anticipating a U.S. recession in the next 12 months. 
The share of consumers who consider a recession somewhat or very likely within the next 12 months has surged to 72%, highlighting the deepest level of economic anxiety in over two years.
With interest rate expectations shifting higher and job prospects dimming, the data paints a clear picture: consumers are tightening their belts and bracing for economic turbulence.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45069781/trumps-first-100-days-what-he-delivered-where-he-fell-short-how-markets-reacted">Trump&#8217;s First 100 Days: What He Delivered, Where He Fell Short, How Markets Reacted</a></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Econ #s

Economics

US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge

Funk is in the air—and now, it's in your pre-roll.
George Clinton, the godfather of funk, is teaming up with <a href="https://www.benzinga.com/markets/cannabis/25/04/42034019/wiz-khalifa-talks-smoking-with-snoop-dreaming-of-bob-marley-riding-horses-with-lenny-kravitz-and">Wiz Khalifa</a> to launch THE FUNK, a new line of infused <a href="https://www.benzinga.com/markets/cannabis/25/04/44929611/why-pre-rolls-are-cannabis-most-profitable-format-from-california-to-canada">cannabis pre-rolls</a> debuting this week at Planet 13 (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNH#OTC">PLNH</a>) Las Vegas, one of the world's largest dispensaries.
The product is dropping Friday, May 2 at 4 p.m. PT, with Clinton appearing for a fan meet-and-greet at Planet 13&#8217;s flagship location at 2548 W Desert Inn Rd. The celebration continues afterward at DAZED!, the onsite consumption lounge.
<h3 class="wp-block-heading">Cosmic Energy Meets Cult Cannabis</h3>
"I'm beyond stoked to be joining forces with my man Wiz Khalifa on this project," said Clinton. "When Wiz first brought up this collab, I instantly knew something cosmic was about to happen. Just like the music lifts your spirit, THE FUNK elevates your consciousness to a whole new dimension. Now you can feel THE FUNK—whether you're spinning our vinyl or sparking something up. It's all the same journey, ya dig?"
For Wiz, the partnership was a no-brainer.
"I love George Clinton. When he said he was down to work on a weed project, I knew we were going to make it extra dope," said Khalifa. "THE FUNK is awesome and will get you high as can be. You need the Funk."
Also read: <a href="https://www.benzinga.com/markets/cannabis/25/04/42034019/wiz-khalifa-talks-smoking-with-snoop-dreaming-of-bob-marley-riding-horses-with-lenny-kravitz-and">Wiz Khalifa Talks Smoking With Snoop, Dreaming Of Bob Marley, Riding Horses With Lenny Kravitz And Selling Weed In Germany</a>
THE FUNK will be sold under the Khalifa Kush umbrella, which opened its first &#8220;store-in-store&#8221; at Planet 13 last summer. The line kicks off with pre-rolls, but according to DJ Saul, CEO of Khalifa Kush, more products—including additional cannabis formats and limited-edition accessories—are already in the works.
<h3 class="wp-block-heading">A Planet 13 Exclusive</h3>
The collaboration adds another chapter to Planet 13&#8217;s growing list of celebrity drops.
"Khalifa Kush is wildly popular at Planet 13 so we're confident THE FUNK will be a hit," said Larry Scheffler, co-CEO of Planet 13. "Having the legendary George Clinton—one of the true pioneers of funk music—join us to celebrate this launch makes the experience even more exciting for our customers."
Planet 13&#8217;s Las Vegas superstore has become a go-to for high-profile brand activations, known for blending cannabis retail with celebrity culture and entertainment.
Photo courtesy of Planet 13

Cannabis

PLNH

Wiz Khalifa Teams Up With George Clinton To Drop An Infused Cannabis Line

Jeff Bezos is <a href="https://www.benzinga.com/personal-finance/25/01/42818961/jeff-bezos-urged-his-brother-and-sister-to-invest-10000-in-amazon-the-stake-grew-15499900-and-its-now-potentially-worth-1-5-billion">known for building Amazon</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) into a trillion-dollar force. But in the early days, even the founder of one of the world's most disruptive companies had moments that could only be described as, well, a little embarrassing.
Speaking at the <a href="https://youtu.be/s7ZvBy1SROE?feature=shared">Academy of Achievement Summit in 2001</a>, Bezos shared a story that proves even the smartest guy in the room can sometimes miss the obvious. Back in 1995, Amazon was nothing more than a scrappy startup operating out of a 2,000-square-foot basement in Seattle. Bezos and a handful of employees, most still working other day jobs, would gather after hours to pack books for the brand-new online bookstore.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
</ul>
"We had so many orders that we weren't ready for that," Bezos said. "We had no real organization in our distribution centers at all. In fact, we were packing on our hands and knees on a hard concrete floor."
It didn't take long for the aches and pains to kick in. "Packing is killing me, you know, my back hurts, this is killing my knees on this hard cement floor," Bezos recalled saying to the employee next to him. Then came his brilliant idea—or so he thought.
"You know what we need, this is my brilliant insight: we need knee pads," he said, dead serious.
The response was immediate—and humbling.
"This person looked at me like I was the stupidest person they'd ever seen," Bezos admitted, laughing at himself. Instead of knee pads, the employee fired back with a much simpler, much smarter idea: "What we need is packing tables."
Trending: Donald Trump Just Announced a $500 Billion AI Infrastructure Deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">Here's How You Can Invest in the Entertainment Market's Next Big Disruptor for Just $998</a>
Bezos didn't miss a beat. "I thought that was the smartest idea I had ever heard," he said. The very next day, they bought packing tables, and according to Bezos, it doubled Amazon's productivity during that critical early stage.
Looking back, <a href="https://www.benzinga.com/news/25/01/42935158/whats-the-internet-jeff-bezos-faced-clueless-investors-before-launching-amazon-had-to-give-up-20-of-the-company-for-only-1-million">Bezos credited moments like these</a> with helping shape Amazon's customer-first culture. "We were so unprepared," he said, calling it "probably one of the luckiest things that ever happened to us because it formed a <a href="https://www.benzinga.com/news/24/06/39175566/jeff-bezos-once-picked-up-the-phone-and-called-amazon-customer-support-to-make-a-point-and-set-off-w">culture of customer service in every department</a>."
Bezos may not have nailed it with the knee pads, but he walked away with something even more valuable: the understanding that the best ideas often come from those closest to the work. Even <a href="https://www.benzinga.com/startups/24/08/40443148/jeff-bezos-said-i-predict-one-day-amazon-will-fail-and-claims-large-companies-only-last-30-plus-year">after stepping down as CEO</a>, he kept building the company around a simple idea — listen to your people, stay obsessed with making things better, and never assume you're the smartest one in the room.
It's a reminder that no title or success protects you from missing the obvious. Sometimes, the smartest move isn't having the first idea — it's recognizing the right one when you hear it. And sometimes, the biggest breakthroughs start with a simple suggestion from the floor.
Read Next:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

Comments

Wizz Air Holdings

Wizz Air Holdings (WZZZY) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL